Pedro Batarda Sena

Dr. Pedro Batarda Sena

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Neurology International
Verified
Journal Article
Open access
PDF file
PSPedro Batarda Sena
Pedro Batarda Sena
MGMarta Gonçalves
Marta Gonçalves
BMBruno Maia
Bruno Maia
MFMargarida Fernandes
Margarida Fernandes
LBLuis Bento
Luis Bento
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe neurocritical condition often complicated by cerebral vasospasm (CVS), leading to delayed cerebral ischemia (DCI) and significant morbidity and mortality. Despite advancements in management, therapeutic options with robust evidence remain limited. Milrinone, a phosphodiesterase type 3 (PDE3) inhibitor, has emerged as a potential therapeutic option. Intravenous milrinone demonstrated clinical and angiographic improvement in 67% of patients, reducing the need for mechanical angioplasty and the risk of functional disability at 6 months (mRS ≤ 2). Side effects, including hypotension, tachycardia, and electrolyte disturbances, were observed in 33% of patients, occasionally leading to early drug discontinuation. Based on the evidence, we propose a treatment algorithm for using milrinone to optimize outcomes and standardize its application in neurocritical care settings.

30 August 2024 in Cureus
Verified
Journal Article
Open access
PDF file
PSPedro Batarda Sena
Pedro Batarda Sena
JRJoao Rodrigues
Joao Rodrigues
FCFrancisco Das Neves Coelho
Francisco Das Neves Coelho
BNBrenda Soares Nunes
Brenda Soares Nunes
OFOrlando Fernandes
Orlando Fernandes
JNJosé J. Nóbrega
José J. Nóbrega
Cardiac arrest is a common cause of death worldwide. Sodium bicarbonate (SB) has commonly been used during cardiopulmonary resuscitation (CPR) to correct metabolic acidosis (MA). However, the existence of evidence about its administration remains controversial. This systematic review aimed to summarize the effectiveness of SB in patients with in-hospital and out-of-hospital cardiac arrest. We searched Medline, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for studies that used SB in cardiac arrest, from November 1962 until December 2023. A total of 372 records were identified and 12 studies were included. Despite few studies suggesting that SB may improve outcomes in prolonged CPR, the overall data revealed that SB was associated with lower rates of ROSC and outcomes. This review conceded that there is limited evidence to warrant the use of SB during CPR other than under specific conditions, which include hyperkalemic cardiac arrest, severe cardiotoxicity, or overdose due to tricyclic antidepressants. In conclusion, SB is not recommended for conventional use in patients with cardiac arrest. Further studies should be performed to determine whether it has any benefit in these scenarios.

1 April 2013 in The Journal of Neuropsychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
PSPedro Batarda Sena
Pedro Batarda Sena
Hipolito NzwaloHipolito Nzwalo
Hipolito Nzwalo
FFFátima Ferreira
Fátima Ferreira
JDJosé Drago
José Drago
LSLuis Soleiro
Luis Soleiro

26 December 2024 in Cureus
Verified
Journal Article
Open access
PSPedro Batarda Sena
Pedro Batarda Sena
MFMargarida Ferro
Margarida Ferro
JCJoana Alves Cabrita
Joana Alves Cabrita
CPCarlos Pontinha
Carlos Pontinha
AMAna Mestre
Ana Mestre
LBLuis Bento
Luis Bento
The diagnosis and management of complex neurological conditions such as New-Onset Refractory Status Epilepticus (NORSE) and central nervous system (CNS) infections caused by non-tuberculous mycobacteria (NTM) pose substantial difficulties in intensive care units (ICUs). This article combines a case report and a literature review that explores the diagnostic dilemmas and therapeutic strategies for these critical conditions.

15 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PSPedro Batarda Sena
Pedro Batarda Sena
MGMarta Gonçalves
Marta Gonçalves
BMBruno Maia
Bruno Maia
MFMargarida Fernandes
Margarida Fernandes
LBLuis Bento
Luis Bento
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe neurocritical condition often complicated by cerebral vasospasm (CVS), leading to delayed cerebral ischemia (DCI) and significant morbidity and mortality. Despite advancements in management, therapeutic options with robust evidence remain limited. Milrinone, a phosphodiesterase type 3 (PDE3) inhibitor, has emerged as a potential therapeutic option. Intravenous milrinone demonstrated clinical and angiographic improvement in 67% of patients, reducing the need for mechanical angioplasty and the risk of functional disability at 6 months (mRS ≤ 2). Side effects, including hypotension, tachycardia, and electrolyte disturbances, were observed in 33% of patients, occasionally leading to early drug discontinuation. Based on the evidence, we propose a treatment algorithm for using milrinone to optimize outcomes and standardize its application in neurocritical care settings.

1 December 2021 in International Journal of Innovative Research in Medical Science
Verified
Journal Article
Open access
PDF file
FSFilipa Silva
Filipa Silva
SRSara Ramos
Sara Ramos
CPCarla Pereira
Carla Pereira
PMPedro Mesquita
Pedro Mesquita
JTJoão Teixeira
João Teixeira
CFCândida Fonseca
Cândida Fonseca
The differential diagnosis of pleural effusion is extensive. Pleural fluid characteristics are helpful in classifying, as transudate or exudate, being this determinant to achieve an accurate diagnosis. The authors present a clinical report of a 74-year-old man with reduced left ventricular ejection fraction heart failure, of ischemic etiology, and multiple cardiovascular risk factors, who develops a pleural effusion. In his medical history it is important to denote a recent diagnosis of colon adenocarcinoma, without evidence of metastatic disease, submitted to hemicolectomy. Four months after this diagnosis, he was admitted in the Emergency Department with dyspnea, type 1 respiratory failure and de novo pleural effusion. The most probable etiologies of pleural effusion were excluded, including heart failure and a metastatic disease. Ultimately, it was reported a difficult (or not so) and unexpected etiology for the pleural effusion, in a patient with multimorbidity and multiple confounders. It is crucial to see beyond the obvious. A real-life challenge for Internal Medicine.